• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of immunotherapy >Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.
【24h】

Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.

机译：在选定的转移性肾细胞癌患者中进行联合免疫化学疗法：HLA II类基因型可以帮助预测对治疗的反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A number of new agents have been approved for systemic therapy of metastatic renal cell carcinoma (mRCC) recently. Thereby, prognostic factors may aid in predicting the effectiveness of various treatment modalities in individual cases. Aim of this study was to determine the value of human leukocyte antigen (HLA) class II characteristics in predicting response of mRCC to combined immunochemotherapy (ICT). A retrospective study of 29 patients with mRCC treated with ICT was performed: 17 patients (group A) with long-term remission and 12 (group B) with progressive disease after ICT. DNA was used for high resolution typing of HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQA1, and -DQB1. Statistical evaluation started with Classification and Regression Trees analysis. The assignment of single alleles to the groups was then aggregated to create a classification on a patients' basis. Finally, the accuracy of this test algorithm was evaluated. HLA-DRB1 (DRB1*0301*0401*0402*0407*1101*1501=progression) was the strongest discriminator between the 2 groups. The test algorithm defined all patients with at least one of these DRB1 alleles to be progressive after ICT. Thus, 12 of 12 patients of group B could have been identified as progressive (sensitivity=100%). However, only 10 of 17 patients of group A would have been identified as responding (specificity=58%). Thus, the test had a positive and negative predictive value of 63% and 100%, respectively. Approximately 5% to 10% of all patients with mRCC are able to benefit from ICT with long-term remission. HLA class II characteristics may aid in identifying this small subgroup of patients with mRCC.
机译：最近，许多新药已被批准用于转移性肾细胞癌（mRCC）的全身治疗。因此，预后因素可能有助于预测个别情况下各种治疗方式的有效性。这项研究的目的是确定人类白细胞抗原（HLA）II类特征在预测mRCC对联合免疫化学疗法（ICT）的反应中的价值。回顾性研究了29例接受ICT治疗的mRCC患者：17例长期缓解的患者（A组）和12例ICT治疗后进行性疾病的患者（B组）。 DNA用于HLA-DRB1，-DRB3，-DRB4，-DRB5，-DQA1和-DQB1的高分辨率分型。统计评估始于分类和回归树分析。然后将单个等位基因分配给各组，以根据患者进行分类。最后，评估了该测试算法的准确性。 HLA-DRB1（DRB1 * 0301 * 0401 * 0402 * 0407 * 1101 * 1501 =级数）是两组之间最强的鉴别力。该测试算法将所有具有至少一种DRB1等位基因的患者定义为在ICT后是进行性的。因此，在B组的12位患者中，有12位可以被确定为进行性（敏感性= 100％）。但是，在A组的17位患者中，只有10位被确认为有反应（特异性= 58％）。因此，该测试的阳性和阴性预测值分别为63％和100％。约有5％至10％的mRCC患者能够长期缓解而受益于ICT。 HLA II类特征可能有助于确定这一小部分mRCC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号